智雲健康(09955.HK):為ClouDT-01申請辦理醫療器械註冊
格隆匯1月3日丨智雲健康(09955.HK)宣佈,於2023年12月29日,集團已在中華人民共和國就ClouDT-01(一款自主研發的糖尿病類數位療法產品)辦妥醫療器械的註冊申請。
ClouDT-01是一款用以管控糖尿病患者的嶄新數位療法產品,效果處於行業領先地位。憑藉本集團先進的數字醫療人工智能大模型、全面的糖尿病服務管理數據庫以及豐富的糖尿病臨牀經驗,ClouDT-01能夠對重要疾病相關指標提供敏感度分析,可供臨牀專業人士及患者參考。ClouDT-01亦促進實時、動態及全面的糖尿病管理,並讓糖尿病患者進一步臨牀獲益。
公司致力發展全球領先的卓越數字健康服務及產品,從而提升醫療保健服務的可及性和可負擔性。公司堅守「讓數字健康走進千家萬户」的使命,積極響應國家政策及「健康中國2030」的目標,推動落實慢病管理相關的創新技術,以期提供優質的數字健康服務及產品,從而惠及更多慢病患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.